Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARC1779 in vWF-Related Platelet Disorders
NCT00632242Phase 2Completed
- Sponsor
- Archemix Corp.
- Start
- Jan 2008
- Primary completion
- Dec 2008
- Modality
- RNA Aptamers, Recombinant Proteins and Enzymes, DNA Aptamers
- Countries
- 1
01
Overview
A Phase 2 trial of egaptivon pegol in thrombotic thrombocytopenic purpura (TTP), von Willebrand disease type 2B (VWD2B), sponsored by Archemix Corp.. Started Jan 2008; status: completed.
02
Drugs
egaptivon pegol
03
Conditions
thrombotic thrombocytopenic purpura (TTP)von Willebrand disease type 2B (VWD2B)
Beyond the preview
Go deeper on NCT00632242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00632242.